Brief: Verrica, Torii Win Japan Approval For YCANTH To Treat Molluscum Contagiosum
19/09/2025 13:27
Sept 19 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O: VERRICA PHARMACEUTICALS ANNOUNCES THAT DEVELOPMENT PARTNER, TORII PHARMACEUTICAL, RECEIVES APPROVAL FOR YCANTH® (TO-208) IN JAPAN FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM VERRICA PHARMACEUTICALS INC - APPROVAL TRIGGERS $10 MILLION MILESTONE PAYMENT TO VERRICA Source text: ID:nGNX9n9knj Further company coverage: VRCA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data